EMA rejects claims of undue industry influence on data disclosure policy
This article was originally published in Scrip
The European Medicines Agency has dismissed suggestions that the 2013 appointment of a new head of legal services with an industry background had a significant influence on the development of its draft policy on clinical trial data disclosure. It has also sharply rejected the idea that it does not pay sufficient attention to the interests of patients.
You may also be interested in...
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.
The EU has ambitious plans for dealing with future health crises, bolstering needs-led innovation, improving access to medicines, and tackling drug shortages.
In its latest communication to medical product companies, the DHSC says the biggest potential cause of disruption to supplies could be failure to prepare for border controls implemented by the EU member states after the end of the Brexit transition period.